CRYO CELL INTERNATIONAL INC CCEL
Cryo-Cell International, Inc. (the "Company" or "Cryo-Cell") is a Delaware corporation that was incorporated in 1989. The Company is organized in three reportable segments; 1.) cellular processing and cryogenic storage for family use, with a current focus on the collection and preservation of umbilical cord blood and tissue stem cells, 2.) the manufacture of PrepaCyte® CB Processing System ("PrepaCyte CB") units, the processing technology used to process umbilical cord blood stem cells, and 3.) cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The Company, in combination with its global affiliates, currently stores over 250,000 cord blood and cord tissue specimens worldwide for the exclusive benefit of newborn babies and possibly other members of their families. Founded in 1989, the Company was the world's first private cord blood bank to separate and store stem cells in 1992. The Company's U.S.-based business operations, including the processing and storage of specimens, are handled from its headquarters facility in Oldsmar, Florida. The specimens are primarily stored in commercially available cryogenic storage units at the Company's technologically and operationally advanced facility in Durham, NC.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $31.6M | $32.0M | $31.3M | $30.3M | $28.9M | $31.1M | $31.8M | $29.2M | $25.4M | $23.1M |
| Cost of revenue | $7.4M | $7.9M | $8.4M | $8.8M | $9.0M | $9.7M | $10.0M | $8.5M | $6.7M | $5.8M |
| Gross profit | $24.2M | $24.0M | $23.0M | $21.5M | $19.9M | $21.5M | $21.8M | $20.7M | $18.7M | $17.4M |
| R&D | $376.3K | $1.2M | $1.2M | $384.8K | $49.9K | $23.9K | $30.1K | $91.8K | $41.2K | $53.1K |
| SG&A | $18.2M | $18.5M | $17.2M | $15.6M | $14.6M | $14.3M | $14.9M | $15.6M | $13.5M | $14.7M |
| Total operating expenses | $31.1M | $28.5M | $43.6M | $26.3M | $24.9M | $23.5M | $26.8M | $24.0M | $20.4M | $22.7M |
| Operating income | $482.4K | $3.5M | -$12.3M | $4.0M | $4.0M | $7.7M | $5.1M | $5.2M | $5.0M | $433.6K |
| Interest expense | $2.1M | $1.9M | $1.2M | $1.5M | $1.4M | $1.5M | $1.7M | $1.5M | $1.3M | $947.3K |
| Pre-tax income | -$2.3M | $2.8M | -$13.4M | $3.3M | $2.6M | $5.0M | $3.4M | $3.6M | $3.6M | -$2.5M |
| Income tax | $92.2K | $2.4M | $3.8M | $547.5K | $527.7K | $1.4M | $1.1M | $4.5M | $1.3M | $1.2M |
| Net income | -$2.4M | $402.1K | -$9.5M | $2.8M | $2.1M | $3.6M | $2.3M | -$854.8K | $2.3M | -$1.3M |
| EPS, basic | -0.30 | 0.05 | -1.14 | 0.33 | 0.26 | 0.48 | 0.29 | -0.11 | 0.33 | -0.16 |
| EPS, diluted | -0.30 | 0.05 | -1.14 | 0.33 | 0.25 | 0.45 | 0.27 | -0.11 | 0.30 | -0.16 |
| Shares, diluted (wtd. avg.) | $8.1M | $8.2M | $8.3M | $8.5M | $8.4M | $8.1M | $8.4M | $7.5M | $7.7M | $8.1M |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $319.0K | $561.0K | $406.1K | $1.7M | $8.3M | $10.4M | $6.5M | $6.0M | $6.3M | $3.5M |
| Short-term investments | $3.0M | $2.9M | $574.2K | $17.6K | $75.4K | $88.5K | $904.1K | $875.7K | $439.3K | $624.2K |
| Receivables | $6.8M | $7.3M | $6.6M | $6.0M | $5.3M | $6.3M | $6.1M | $5.9M | $5.1M | $4.1M |
| Inventory | $408.8K | $657.7K | $768.9K | $851.2K | $921.2K | $927.3K | $1.1M | $1.3M | $314.6K | $361.1K |
| Total current assets | $11.8M | $12.6M | $9.5M | $9.6M | $15.8M | $18.6M | $15.4M | $14.8M | $12.7M | $9.0M |
| Property, plant and equipment | $21.0M | $21.9M | $21.0M | $13.6M | $3.2M | $1.6M | $1.8M | $1.5M | $882.4K | $979.5K |
| Goodwill | $1.9M | $1.9M | $1.9M | $1.9M | $1.9M | $1.9M | $1.9M | $1.9M | $0 | $0 |
| Other intangibles | $863.1K | $921.3K | $989.1K | $1.5M | $1.6M | $1.2M | $1.2M | $1.3M | $226.4K | $261.0K |
| Total assets | $61.7M | $64.7M | $61.2M | $64.9M | $60.7M | $46.2M | $42.9M | $42.4M | $23.9M | $19.5M |
| Accounts payable | $2.9M | $1.9M | $3.2M | $1.6M | $1.5M | $957.4K | $1.4M | $1.3M | $1.9M | $1.5M |
| Total current liabilities | $19.8M | $21.6M | $20.9M | $19.5M | $21.1M | $16.4M | $15.4M | $15.4M | $13.9M | $13.1M |
| Long-term debt | $8.4M | $8.5M | $8.6M | $8.7M | $1.9M | $5.9M | $9.0M | $12.9M | $1.4M | $1.4M |
| Total liabilities | $80.3M | $77.9M | $72.3M | $66.4M | $56.5M | $48.9M | $49.8M | $51.3M | $36.4M | $35.0M |
| Retained earnings | -$38.4M | -$32.8M | -$31.2M | -$21.6M | -$16.7M | -$18.8M | -$22.4M | -$25.3M | -$24.5M | -$26.8M |
| Total equity | -$18.6M | -$13.2M | -$11.0M | -$1.5M | $4.2M | -$2.7M | -$7.0M | -$8.9M | -$12.5M | -$15.4M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $5.5M | $6.0M | $8.9M | $8.6M | $7.9M | $8.5M | $6.3M | $5.3M | $5.7M | $5.0M |
| Depreciation and amortisation | $985.2K | $693.8K | $1.4M | $1.5M | $1.0M | $372.3K | $401.3K | $317.3K | $230.0K | $243.0K |
| Stock-based compensation | $417.1K | $781.1K | $816.6K | $461.3K | $301.6K | $622.1K | $397.8K | $478.4K | $971.7K | $1.8M |
| Capital expenditure | $230.5K | $2.4M | $6.8M | $12.2M | $1.8M | $100.0K | $662.3K | $446.2K | $98.3K | $343.0K |
| Investing cash flow | -$975.3K | -$4.9M | -$8.1M | -$15.3M | -$7.0M | $357.5K | -$662.3K | -$11.3M | $93.0K | -$369.7K |
| Financing cash flow | -$4.7M | -$979.1K | -$2.1M | $147.9K | -$3.1M | -$5.0M | -$5.1M | $5.7M | -$3.0M | -$5.3M |
| Dividends paid | $3.2M | $2.0M | $0 | $7.7M | $0 | — | — | — | — | — |
| Buybacks | $169.5K | $1.4M | $799.0K | $1.8M | $249.4K | — | $992.2K | — | $446.6K | $10.8M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-083096.
Others in SIC 8090
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| DVA | DAVITA INC. | $11.74B | 18.7x | 6.5% |
| SHC | Sotera Health Co | $5.39B | 70.0x | 5.7% |
| PGNY | Progyny, Inc. | $1.99B | 39.9x | 10.4% |
| AGL | agilon health, inc. | $1.49B | — | -2.1% |
| VMD | VIEMED HEALTHCARE, INC. | $345.8M | 24.5x | 20.5% |
| MGRX | MANGOCEUTICALS, INC. | $8.9M | — | -26.0% |
| BRTX | BioRestorative Therapies, Inc. | $3.8M | — | -10.3% |
| FMS | Fresenius Medical Care AG | — | — | — |